AbbVie Acquires Apogee for $10.9 Billion in Major Pharmaceutical Deal
In a significant move for the pharmaceutical industry, AbbVie has announced its acquisition of Apogee for $10.9 billion, marking its largest deal in over five years amid a wave of mergers and acquisitions.
Editorial Staff
1 min read
Updated about 17 hours ago
AbbVie has finalized a deal to purchase Apogee for $10.9 billion, a transaction that underscores the company's strategic focus on inflammatory disease treatments.
This acquisition represents AbbVie's largest investment in more than five years, highlighting the ongoing trend of mergers and acquisitions within the pharmaceutical sector.
As the industry experiences a surge in consolidation, this move may position AbbVie to enhance its portfolio and competitive edge in the market.